Title:
ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/218384
Kind Code:
A1
Abstract:
An anti-CD47 monoclonal antibody and the use thereof in combination with a monoclonal antibody, a bispecific antibody and/or a tumor therapeutic agent, wherein the anti-CD47 monoclonal antibody is secreted by a hybridoma cell line with a deposit number of CCTCC NO: C2018135.
More Like This:
| WO/2006/084264 | CD20 ANTIBODY VARIANTS AND USES THEREOF |
| WO/1995/014779 | MUTATED HIG-E FRAGMENTS AND DERIVATIVE THEREOF |
| WO/2016/149678 | NON-HUMAN ANIMALS THAT SELECT FOR LIGHT CHAIN VARIABLE REGIONS THAT BIND ANTIGEN |
Inventors:
LI BAIYONG (CN)
XIA YU (CN)
WANG ZHONGMIN MAXWELL (CN)
XIA YU (CN)
WANG ZHONGMIN MAXWELL (CN)
Application Number:
PCT/CN2022/086890
Publication Date:
October 20, 2022
Filing Date:
April 14, 2022
Export Citation:
Assignee:
AKESO BIOPHARMA INC (CN)
AKESO PHARMACEUTICALS INC (CN)
AKESO PHARMACEUTICALS INC (CN)
International Classes:
C07K16/28; C07K19/00; C12N15/13
Domestic Patent References:
| WO2021004480A1 | 2021-01-14 | |||
| WO1988001649A1 | 1988-03-10 |
Foreign References:
| CN112442123A | 2021-03-05 | |||
| CN112300286A | 2021-02-02 | |||
| CN112830972A | 2021-05-25 | |||
| US4946778A | 1990-08-07 | |||
| US5260203A | 1993-11-09 | |||
| US4816567A | 1989-03-28 | |||
| US5747654A | 1998-05-05 |
Other References:
FENG, DONGDONG ET AL.: "Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia", BLOOD, vol. 132, no. supplement 1, 29 November 2018 (2018-11-29), XP086590116, DOI: 10.1182/blood-2018-99-120170
LIAN SHU, XIE RUIZHI, YE YUYING, LU YUSHENG, CHENG YUNLONG, XIE XIAODONG, LI SHUHUI, JIA LEE: "Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells", SCIENTIFIC REPORTS, NATURE PUBLISHING GROUP, vol. 9, no. 1, 14 December 2019 (2019-12-14), XP055884207, DOI: 10.1038/s41598-019-40241-1
HUA TAO, QIAN PUDONG, WANG FEIJIANG, YU HONGLIANG, GUO YESONG: "Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model", ONCOLOGY RESEARCH., PERGAMON PRESS, NEW YORK, NY., US, vol. 25, no. 9, 2 November 2017 (2017-11-02), US , pages 1579 - 1587, XP055540506, ISSN: 0965-0407, DOI: 10.3727/096504017X14900505020895
ZHAO LEI, LINGLING LI, SHIXUE CHEN, YI HU: "Computational design of novel tetra-specific antibody (PD-1/CD47/VEGF/TGF-ß) with IgG-like architecture against non-small cell lung cancer (NSCLC). | Journal of Clinical Oncology", JOURNAL OF CLINICAL ONCOLOGY, pages 1 - 4, XP055906329, Retrieved from the Internet [retrieved on 20220329]
WATERSONE HANXBIO PTY LTD: "NCT04097769 The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies", CLINICALTRIALS, 23 September 2019 (2019-09-23), XP009540398
MATOZAKI TMURATA YOKAZAWA H ET AL.: "Functions and molecular mechanisms of the CD47-SIRPa signaling pathway", TRENDS IN CELL BIOLOGY, vol. 19, no. 2, 2009, pages 72 - 80
OLDENBORG P AZHELEZNYAK AFANG Y F ET AL.: "Role of CD47 as a marker of self on red blood cells", SCIENCE, vol. 288, no. 5473, 2000, pages 2051 - 2054, XP055304810, DOI: 10.1126/science.288.5473.2051
JIANG PLAGENAUR CFNARAYANAN V: "Integrin-associated Protein Is a Ligand for the P84 Neural Adhesion Molecule", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 1999, pages 559 - 62
JAISWAL SJAMIESON C H MPANG W W ET AL., CELL, vol. 138, no. 3, 2009, pages 271 - 285
VONDERHEIDE R H, NATURE MEDICINE, vol. 21, no. 10, 2015, pages 1122
"GenBank", Database accession no. NP-542970.1
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
LIU JIANJUN, CHINESE JOURNAL OF CELLULAR AND MOLECULAR IMMUNOLOGY, vol. 1989, no. 4, pages 29 - 29
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA., vol. 90, 1988, pages 5879 - 5883
SONGSIVILAILACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321
KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
REICHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
CLARK, IMMUNOL. TODAY, vol. 21, 2000, pages 397 - 402
REITER ET AL., NAT. BIOTECHNOL., vol. 14, 1996, pages 1239 - 1245
RAJAGOPAL ET AL., PROT. ENGIN., vol. 10, 1997, pages 1453 - 1459
REITER ET AL., PROTEIN ENGINEERING, vol. 8, 1995, pages 1323 - 1331
WEBBER ET AL., MOLECULAR IMMUNOLOGY, vol. 32, 1995, pages 249 - 258
REITER ET AL., IMMUNITY, vol. 2, 1995, pages 281 - 287
REITER ET AL., JBC, vol. 269, 1994, pages 18327 - 18331
REITER ET AL., INTER J. OF CANCER, vol. 58, 1994, pages 142 - 149
REITER ET AL., CANCER RES., vol. 54, 1994, pages 2714 - 2718
PEARSON, METHODS MOL. BIOL., vol. 243, 1994, pages 307 - 31
GONNET ET AL., SCIENCE, vol. 256, 1992, pages 1443 - 45
PEARSON, METHODS ENZYMOL., vol. 183, 1990, pages 63 - 98
PEARSON, METHODS MOL. BIOL., vol. 132, 2000, pages 185 - 219
ALTSCHUL ET AL., MOL. BIOL., vol. 215, 1990, pages 403 - 410
AL TSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 402
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
ACIERNO ET AL.: "Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies", J MOL BIOL., vol. 374, no. 1, 2007, pages 130 - 46, XP022310713, DOI: 10.1016/j.jmb.2007.09.005
WHO DRUG INFORMATION, vol. 34, no. 2, 2020, pages 375 - 376
HAGE TREINEMER PSEBALD W.: "Crystals of a 1:1 Complex Between Human Interleukin-4 and the Extracellular Domain of Its Receptor Alpha Chain", EUR. J. BIOCHEM., vol. 258, no. 2, 1998, pages 831 - 6, XP003018346, DOI: 10.1046/j.1432-1327.1998.2580831.x
"Molecular Cloning: A Laboratory Manual"
LIAN SHU, XIE RUIZHI, YE YUYING, LU YUSHENG, CHENG YUNLONG, XIE XIAODONG, LI SHUHUI, JIA LEE: "Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells", SCIENTIFIC REPORTS, NATURE PUBLISHING GROUP, vol. 9, no. 1, 14 December 2019 (2019-12-14), XP055884207, DOI: 10.1038/s41598-019-40241-1
HUA TAO, QIAN PUDONG, WANG FEIJIANG, YU HONGLIANG, GUO YESONG: "Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model", ONCOLOGY RESEARCH., PERGAMON PRESS, NEW YORK, NY., US, vol. 25, no. 9, 2 November 2017 (2017-11-02), US , pages 1579 - 1587, XP055540506, ISSN: 0965-0407, DOI: 10.3727/096504017X14900505020895
ZHAO LEI, LINGLING LI, SHIXUE CHEN, YI HU: "Computational design of novel tetra-specific antibody (PD-1/CD47/VEGF/TGF-ß) with IgG-like architecture against non-small cell lung cancer (NSCLC). | Journal of Clinical Oncology", JOURNAL OF CLINICAL ONCOLOGY, pages 1 - 4, XP055906329, Retrieved from the Internet
WATERSONE HANXBIO PTY LTD: "NCT04097769 The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies", CLINICALTRIALS, 23 September 2019 (2019-09-23), XP009540398
MATOZAKI TMURATA YOKAZAWA H ET AL.: "Functions and molecular mechanisms of the CD47-SIRPa signaling pathway", TRENDS IN CELL BIOLOGY, vol. 19, no. 2, 2009, pages 72 - 80
OLDENBORG P AZHELEZNYAK AFANG Y F ET AL.: "Role of CD47 as a marker of self on red blood cells", SCIENCE, vol. 288, no. 5473, 2000, pages 2051 - 2054, XP055304810, DOI: 10.1126/science.288.5473.2051
JIANG PLAGENAUR CFNARAYANAN V: "Integrin-associated Protein Is a Ligand for the P84 Neural Adhesion Molecule", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 1999, pages 559 - 62
JAISWAL SJAMIESON C H MPANG W W ET AL., CELL, vol. 138, no. 3, 2009, pages 271 - 285
VONDERHEIDE R H, NATURE MEDICINE, vol. 21, no. 10, 2015, pages 1122
"GenBank", Database accession no. NP-542970.1
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
LIU JIANJUN, CHINESE JOURNAL OF CELLULAR AND MOLECULAR IMMUNOLOGY, vol. 1989, no. 4, pages 29 - 29
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA., vol. 90, 1988, pages 5879 - 5883
SONGSIVILAILACHMANN, CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321
KOSTELNY ET AL., J. IMMUNOL., vol. 148, 1992, pages 1547 - 1553
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
REICHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
CLARK, IMMUNOL. TODAY, vol. 21, 2000, pages 397 - 402
REITER ET AL., NAT. BIOTECHNOL., vol. 14, 1996, pages 1239 - 1245
RAJAGOPAL ET AL., PROT. ENGIN., vol. 10, 1997, pages 1453 - 1459
REITER ET AL., PROTEIN ENGINEERING, vol. 8, 1995, pages 1323 - 1331
WEBBER ET AL., MOLECULAR IMMUNOLOGY, vol. 32, 1995, pages 249 - 258
REITER ET AL., IMMUNITY, vol. 2, 1995, pages 281 - 287
REITER ET AL., JBC, vol. 269, 1994, pages 18327 - 18331
REITER ET AL., INTER J. OF CANCER, vol. 58, 1994, pages 142 - 149
REITER ET AL., CANCER RES., vol. 54, 1994, pages 2714 - 2718
PEARSON, METHODS MOL. BIOL., vol. 243, 1994, pages 307 - 31
GONNET ET AL., SCIENCE, vol. 256, 1992, pages 1443 - 45
PEARSON, METHODS ENZYMOL., vol. 183, 1990, pages 63 - 98
PEARSON, METHODS MOL. BIOL., vol. 132, 2000, pages 185 - 219
ALTSCHUL ET AL., MOL. BIOL., vol. 215, 1990, pages 403 - 410
AL TSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 402
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
ACIERNO ET AL.: "Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies", J MOL BIOL., vol. 374, no. 1, 2007, pages 130 - 46, XP022310713, DOI: 10.1016/j.jmb.2007.09.005
WHO DRUG INFORMATION, vol. 34, no. 2, 2020, pages 375 - 376
HAGE TREINEMER PSEBALD W.: "Crystals of a 1:1 Complex Between Human Interleukin-4 and the Extracellular Domain of Its Receptor Alpha Chain", EUR. J. BIOCHEM., vol. 258, no. 2, 1998, pages 831 - 6, XP003018346, DOI: 10.1046/j.1432-1327.1998.2580831.x
"Molecular Cloning: A Laboratory Manual"
Attorney, Agent or Firm:
BEIJING C&S LAW FIRM (CN)
Download PDF:
Previous Patent: USE OF ANTIBODY IN ANTI-TUMOR TREATMENT
Next Patent: UNIFIED NEURAL NETWORK FILTER MODEL
Next Patent: UNIFIED NEURAL NETWORK FILTER MODEL